uniform collection and central storage of data and body material for the multidisciplinary cooperative SKION-LATER group

Published: 18-05-2009
Last updated: 06-05-2024

To support future scientific research into late effects of treatment for childhood cancer

Ethical review	Approved WMO
Status	Pending
Health condition type	Other condition
Study type	Observational invasive

Summary

ID

NL-OMON33692

Source
ToetsingOnline

Brief title
SKION LATER registry and biobank

Condition

- Other condition

Synonym
late effects of treatment for childhood cancer

Health condition

de registratie en biobank zijn ondersteunende structuren voor wetenschappelijk onderzoek naar breed scala van late effecten

Research involving
Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum
Source(s) of monetary or material Support: KWF Kankerbestrijding en Stichting KIKA

Intervention

Keyword: body material, data, late effects, pediatric oncology

Outcome measures

Primary outcome

NA

Secondary outcome

NA

Study description

Background summary

Survival rates for childhood cancer have risen beyond 75%; unfortunately, a growing number of long-term survivors of these diseases are faced with adverse health effects from their cancer treatments. Seven Dutch centers for pediatric oncology and stem cell transplantation have joint forces in a multidisciplinary cooperative group called LATER: Late Effects following childhood cancer treatment, within the pre-exisiting structures of the Dutch Childhood Oncology Group (DCOG).
The goals are defined as follows: to offer adequate patientcare for this new group of patients and to conduct scientific research into late effects of treatment for childhood cancer.

This proposal describes the DCOG-LATER registry and biobank, both intended to support future scientific research and to ameliorate patientcare for survivors of childhood cancer.

Study objective

To support future scientific research into late effects of treatment for childhood cancer

Study design

Cohortstudy with retrospective and prospective in-flow of childhood cancer survivors and prospective follow-up, including an extra tube of blood for the biobank.

Study burden and risks

Burden: completion of a questionnaire and obtaining an extra tube of blood or a saliva sample
Risks: very small chance to detect yet unknown conditions ("coincidental finding") when body material is processed in the future

Contacts

Public
Academisch Medisch Centrum

Meibergdreef 9
1100 DD Amsterdam
NL
Scientific
Academisch Medisch Centrum

Meibergdreef 9
1100 DD Amsterdam
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adolescents (12-15 years)
Adolescents (16-17 years)
Adults (18-64 years)
Children (2-11 years)
Elderly (65 years and older)

Inclusion criteria

- diagnosis of childhood cancer or related conditions and survival of at least 5 yrs post-diagnosis
- treated (in part) by a pediatric oncologist in one of seven participating academic hospitals
- resident of the Netherlands at the time of diagnosis
- age at diagnosis 17 years or younger

Exclusion criteria

diagnosis of childhood cancer with survival less than 5 years, age at diagnosis >17 years or diagnosis while residing in foreign country

Study design

Design

Study type:	Observational invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Other

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	01-07-2008
Enrollment:	6850
Type:	Anticipated

Ethics review

Approved WMO

Application type:	First submission

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL23633.018.08